| 1. |
- Holdaas, H., et al.
(författare)
-
Effect of fluvastatin on cardiac outcomes in renal transplant recipients : A multicentre, randomised, placebo-controlled trial
- 2003
-
Ingår i: The Lancet. - 0140-6736 .- 1474-547X. ; 361:9374, s. 2024-2031
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Renal transplant recipients are at increased risk of premature cardiovascular disease. Although statins reduce cardiovascular risk in the general population, their efficacy and safety in renal transplant recipients have not been established. We investigated the effects of fluvastatin on cardiac and renal endpoints in this population. Methods: We did a multicentre, randomised, double-blind, placebo-controlled trial in 2102 renal transplant recipients with total cholesterol 4·0-9·0 mmol/L. We randomly assigned patients fluvastatin (n=1050) or placebo (n=1052) and follow up was for 5-6 years. The primary endpoint was the occurrence of a major adverse cardiac event, defined as cardiac death, non-fatal myocardial infarction (MI), or coronary intervention procedure. Secondary endpoints were individual cardiac events, combined cardiac death or non-fatal MI, cerebrovascular events, non-cardiovascular death, all-cause mortality, and graft loss or doubling of serum creatinine. Analysis was by intention to treat. Findings: After a mean follow-up of 5·1 years, fluvastatin lowered LDL cholesterol concentrations by 32%. Risk reduction with fluvastatin for the primary endpoint (risk ratio 0·83 [95% CI 0·64-1·06], p=0·139) was not significant, although there were fewer cardiac deaths or non-fatal MI (70 vs 104, 0·65 [0·48-0·88] p=0·005) in the fluvastatin group than in the placebo group. Coronary intervention procedures and other secondary endpoints did not differ significantly between groups. Interpretation: Although cardiac deaths and non-fatal MI seemed to be reduced, fluvastatin did not generally reduce rates of coronary intervention procedures or mortality. Overall effects of fluvastatin were similar to those of statins in other populations.
|
|
| 2. |
- Terazono, Y., et al.
(författare)
-
Photonic control of photoinduced electron transfer via switching of redox potentials in a photochromic moiety
- 2004
-
Ingår i: Journal of Physical Chemistry B. ; 108:6, s. 1812-1814
-
Tidskriftsartikel (refereegranskat)abstract
- A porphyrin (P) has been covalently linked to a photochromic dihydroindolizine moiety (DHI) to form a P-DHI dyad. When the dihydroindolizine is in its closed, spirocyclic form (DHIc), the photophysics of the attached porphyrin are unaffected. Irradiation with UV light opens the photochromic moiety to the betaine form (DHIo), which has a significantly higher reduction potential than DHIc. Light absorption by the porphyrin moiety of P-DHIo is followed by rapid (50 ps) photoinduced electron transfer to yield the P.+-DHIo(.-) charge-seperated state. This state recombines in 2.9 ps to give the ground state. Irradiation of P-DHIo with light at wavelengths > 590 nm induces photoisomerization back to P-DHIc. Thermal closing can also be achieved. Thus, light is used to switch photoinduced electron transfer on or off. These principles may be useful in the design of molecular optoelectronic devices.
|
|
